Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study
Authors:
- Jan N. BasileJBJan N. Basile
- Anthony N. VoAVAnthony N. Vo
- Ping JiangPJPing Jiang
- Roopal ThakkarRTRoopal Thakkar
- Robert J. PadleyRPRobert J. Padley
- 1 April 2009
- journal article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 3 (2) , 109-118
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular EventsNew England Journal of Medicine, 2007
- High-Density Lipoprotein as a Therapeutic TargetJAMA, 2007
- Plasma Lipoprotein(a) Indicates Risk for 4 Distinct Forms of Vascular DiseaseClinical Chemistry, 2007
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk FactorsCirculation, 2000
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study1996
- Epidemiology of triglycerides: A view from FraminghamThe American Journal of Cardiology, 1992
- High density lipoprotein as a protective factor against coronary heart diseaseThe American Journal of Medicine, 1977